Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Pope trip to Luxembourg, Belgium confirmed for September, 2 weeks after challenging Asia visit
Details of UK military personnel exposed in huge payroll data breach
Xi to begin Serbia visit on the 25th anniversary of NATO's bombing of the Chinese Embassy
Georgia court candidate sues to block ethics rules so he can keep campaigning on abortion
Jude Bellingham's new model girlfriend Laura Celia Valk looks sensational in a figure
Australian boy killed by police was in deradicalization program since causing school explosion
Rihanna shows off her bold pink hair as she supports baby daddy A$AP Rocky at Puma pop
DeLuca stays hot with homer and 4 RBIs as Rays beat Clevinger and White Sox 8
Target starts price war with Walmart by slashing the cost of 5,000 popular items
Georgia court candidate sues to block ethics rules so he can keep campaigning on abortion
With Djokovic awaiting the winner, Murray trails Hanfmann at rain
Lured by Rolling Stones performance, half